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Purpose: Physical activity (PA) has been linked to a reduced risk of type 2 diabetes by reducing weight 
and improving insulin sensitivity. We investigated whether PA is associated with a lower incidence of 
latent autoimmune diabetes in adults (LADA) and whether the association is modified by genotypes of 
human leukocyte antigen (HLA), transcription factor 7-like 2 (TCF7L2)-rs7903146, or the fat mass and 
obesity-associated gene, FTO-rs9939609.
Methods: We combined data from a Swedish case-control study and a Norwegian prospective study 
including 621 incident cases of LADA and 3596 cases of type 2 diabetes. We estimated adjusted pooled 
relative risks (RRs) and 95% CI of diabetes in relation to high (≥ 30 minutes of moderate activity 3 times/
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Results: High PA was associated with a reduced risk of LADA (RR 0.61; CI, 0.43-0.86), which was 
attenuated after adjustment for body mass index (BMI) (RR 0.90; CI, 0.63-1.29). The reduced risk applied 
only to noncarriers of HLA-DQB1 and -DRB1 (RR 0.49; CI, 0.33-0.72), TCF7L2 (RR 0.62; CI, 0.45-0.87), and 
FTO (RR 0.51; CI, 0.32-0.79) risk genotypes. Adjustment for BMI attenuated but did not eliminate these 
associations. For type 2 diabetes, there was an inverse association with PA (RR 0.49; CI, 0.42-0.56), 
irrespective of genotype.
Main Conclusions: Our findings indicate that high PA is associated with a reduced risk of LADA in 
individuals without genetic susceptibility.
Freeform/Key Words: physical activity, gene-environment interaction, LADA, latent autoimmune diabetes in adults, 
type 2 diabetes, population-based
Physical activity (PA) is associated with a reduced risk of 
type 2 diabetes, as shown both in observational (1) and 
intervention studies (2). The physiological pathways po-
tentially linking PA to improved glucose uptake involve 
beneficial effects on body weight as well as direct effects 
on insulin sensitivity (3). PA has also been associated with 
improved insulin secretion as a result of decrease in β-cell 
lipid accumulation (4). Whether PA may also prevent or 
postpone autoimmune forms of diabetes is not clear.
Latent autoimmune diabetes in adults (LADA) is a 
common form of diabetes, characterized by mild auto-
immunity and slower progression to insulin dependence 
than what is seen in type 1 diabetes, together with fea-
tures of type 2 diabetes such as insulin resistance (5) and 
overweight (6). Similar to type 2 diabetes, PA might also 
prevent LADA through reducing overweight and insulin 
resistance or improving insulin secretion. On the other 
hand, PA might also act through a pathway involving auto-
immunity; an in vitro study of children found that high PA 
may have positive effects on the immune system by altering 
autoantigen-induced immune activity (7). Support for a 
protective effect of PA on LADA risk comes from a small 
study based on 11 years’ follow-up of the Nord-Trøndelag 
Health Study (HUNT) (8), but that study included only 81 
cases and could not address underlying mechanisms. We 
are not aware of any other study on the association be-
tween PA and the risk of autoimmune diabetes in adults or 
in children.
Similar to type 1 diabetes, human leukocyte antigen 
(HLA) genotypes, particularly in the HLA-DRB1 and 
DQB1 genes, confer a high risk of LADA (9-11). LADA 
has also been linked to genes associated with type 2 dia-
betes, for example, risk variants of the transcription factor 
7-like 2 (TCF7L2) gene (12-14) and in one study, with 
the fat mass and obesity-associated (FTO) gene (15). We 
have recently shown that overweight and high-risk geno-
types of HLA, TCF7L2, and FTO interact in relation to 
the risk of LADA (16). At the same time, the effect of FTO 
on risk of obesity is attenuated by PA (17). Hence it can 
be hypothesized that the impact of PA on LADA risk de-
pends on genetic susceptibility. The aim of this study was 
to investigate the association between PA and incidence of 
LADA compared with the associations regarding type 2 
diabetes, as well as whether these associations are modi-
fied by HLA, FTO, or TCF7L2 genotypes and potential 
underlying mechanisms. We used updated data from the 
prospective HUNT study, including 22 years of follow-up 
and more than twice as many cases of LADA and type 2 
diabetes as the previous study (8), and newly collected data 
from a Swedish case-control study with incident cases.
Materials and Methods
The ESTRID study
Study population. ESTRID (Epidemiological Study of 
Risk Factors for LADA and Type 2 Diabetes) (18) (Extra 
Supplemental Material [ESM] Fig. 1)  (19) is an ongoing 
population-based case-control study from Sweden created 
with the purpose of studying lifestyle factors in relation to 
incidence of LADA and type 2 diabetes. ESTRID is nested 
in ANDIS (All New Diabetics in Scania), an extensive 
diabetes registry and biobank, aiming at classifying all new 
cases of diabetes within Scania County (20) and ANDiU (All 
New Diabetics in Uppsala County), a similar registry in the 
County of Uppsala. To the ESTRID study we have invited 
all incident cases of LADA and a random sample of type 
2 diabetes cases registered in ANDIS (95% of cases) since 
2010 and ANDiU (5% of cases) since 2012 and collected 
questionnaire information (within a median of 5 months 
after diagnosis for cases) in addition to clinical and genetic 
information obtained from the diabetes registries. Control 
individuals without diabetes (age ≥ 35 years) are randomly 
sampled through the national population register (6/
LADA case) and matched to cases through incidence 
density matching (21). The controls provide questionnaire 
information but there is no genetic information. For 
the purpose of the genetic analyses of the present paper, 
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(Epidemiological Investigation of Rheumatoid Arthritis), 
which uses a similar questionnaire in addition to a biobank 
(22). These controls, which we hereafter will refer to as 
“genetic controls,” are randomly selected from the Swedish 
population registry, free of diabetes, and matched to our 
cases by age and sex.
Our analytical sample includes all cases and controls 
with complete information on PA and all covariates, en-
rolled in ESTRID between 2010 and 2017 (LADA n = 474 
[393 with genetic information], type 2 diabetes n = 1594 
[1286 with genetic information], controls n = 1886); to-
gether with genetic control individuals who were all 
controls recruited to the EIRA study between 2006 and 
2014 with information on PA, all covariates, and at least 
one of the genotypes of interest (n = 1557). All participants 
gave their written informed consent and the regional eth-
ical review board in Stockholm approved the study.
Diabetes classification. Patients were diagnosed within 
the health care system of Scania and classified as LADA if 
they were 35 years or older, glutamic acid decarboxylase 
antibody (GADA) positive (≥ 10.7 IU/mL, enzyme-linked 
immunosorbent assay, RSR Limited), and had fasting serum 
C-peptide levels of 0.2  nmol/L or greater (IMMULITE 
2000 [Siemens Healthcare Diagnostics Product Ltd]) 
or 0.3  nmol/L or greater (Cobas e 601 analyzer, Roche 
Diagnostics). Patients with type 2 diabetes were GADA 
negative and had C-peptide greater than 0.6  nmol/L 
(IMMULITE) or greater than 0.72  nmol/L (Cobas). At 
the GADA cutoff point 10.7 IU/mL specificity was 98% 
and sensitivity 84% (23). Homeostasis model assessment 
(HOMA)–measure of insulin resistance (IR) and HOMA-β 
(estimating β-cell function) were calculated based on fasting 
plasma glucose and serum C-peptide (24).
Genetic information. Blood samples for genotyping of 
patients were analyzed at the Clinical Research Center in 
Malmö, Sweden, using iPlex Gold Technology (Sequenom). 
Missing genotypes were imputed for a subset using Infinium 
CoreExome v1.1 (Illumina) based on the Haplotype 
Reference Consortium (http://www.haplotype-reference-
consortium.org/; version r1.1 2016)  reference panel. 
Controls were genotyped based on genome-wide association 
study data generated through an Illumina Global Screening 
array or an Infinium Illumina 300K immunochip custom 
array. Three single-nucleotide variations (SNVs, formerly 
single-nucleotide polymorphisms [SNPs]) (rs3104413, 
rs2854275, rs9273363) were used to define HLA-DRB1 
and DQB1 genotypes associated with high (DR4/4, DR3/3, 
DR3/4, DR3/4-DQ8, DR4/4-DQ8, DR4/X-DQ8) or low/
intermediate (DR4/X, DR3/X, DRX/X, DR4-DQ7) risk for 
type 1 diabetes. The selection of HLA-genotyped SNVs was 
based on a validated method with an overall accuracy of 
99.3% (25). The TCF7L2 gene was genotyped with SNV 
rs7903146 and the FTO gene with SNV rs9939609.
The HUNT study
Study population. In the northern part of the Norwegian 
county of Trøndelag, 3 health surveys were conducted 
between 1984 and 2008 (HUNT1, 1984-1986; HUNT2, 
1995-1997; HUNT3, 2006-2008) with the aim of studying 
a range of health outcomes, including diabetes (26) (ESM 
Fig. 2) (19). The surveys targeted all residents aged 20 years 
or older, and participants completed a questionnaire 
with items on health and lifestyle and attended in a 
clinical examination that included blood sampling and 
measurements of height and weight. Based on these cross-
sectional studies, we have formed a cohort consisting of 
those who participated in at least 2 surveys, and at baseline 
were free of diabetes and with information on PA and all 
covariates (n = 54 258 [46 567 with genetic information]). 
Informed consent was given by all participants and the 
study was approved by the Norwegian Data Protection 
Authority and the Regional Committee for Medical and 
Health Research Ethics.
Diabetes classification.  Incident cases of diabetes were 
identified by self-reporting at HUNT2 or HUNT3. 
A previous validation study shows that these self-reports 
correctly classify more than 95% of patients (27). Fasting 
blood samples were collected at follow-up in HUNT 
(median, 4  years after diagnosis) and based on this, all 
patients with diagnosis at age 35  years or older were 
classified as having LADA (n = 147) if they were GADA 
positive (≥ 43 IU/mL, immunoprecipitation radioligand 
assay Novo Nordisk) and as having type 2 diabetes if they 
were GADA negative (n = 2002). At the positive cutoff for 
GADA, specificity was 1.00 and sensitivity 0.64 according 
to the IASP (Islet Autoantibody Standardization Program) 
2003 workshop. This LADA definition implies that some 
patients with adult-onset type 1 diabetes will be included. 
As discussed previously, the proportion of such patients is 
likely to be small (6). HOMA indices were calculated based 
on fasting serum C-peptide and fasting serum or whole-
blood glucose, measured as described previously.
Genetic information. DNA samples were analyzed at 
the NTNU Genomic Core Facility in Trondheim using 
HumanCoreExome arrays (Illumina, https://www.ntnu.
no/hunt/gwas-data) and genotyped for SNVs associated 
with HLA-DRB1 and HLA-DQB1 (rs2854275, 
rs9273363, rs9272346), TCF7L2 (rs7903146), and FTO 
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(v2.0.1, http://genome.sph.umich.edu/wiki/Minimac3) 
from a customized Haplotype Reference consortium 
release 1.1 (HRC v1.1). For the HLA analysis, 3 
SNVs (rs2854275, rs9273363, rs9272346) previously 
associated with LADA and type 1 diabetes (20, 25, 28, 
29) were chosen based on the availability in our study 
sample. Out of these, rs2854275 and rs9273363 were also 
used in ESTRID. Participants were classified as having an 
HLA high-risk genotype if carrying at least one of the 
risk variants inferring DR3-DQ2 haplotype; rs2854275 
(TT/TG) and rs9272346 (AA) or DR4-DQ8 haplotype; 
rs9273363 (AA), and the others were considered to have 
low/moderate risk.
Physical activity. In ESTRID, information on PA (see 
Appendix for detailed information on all questions in 
ESTRID and HUNT) (19) was obtained by a question 
on average leisure time PA during the previous year, that 
is, the year prior to diagnosis in diabetic patients. There 
were 4 response alternatives, ranging from 1) sedentary; 
moderate PA for less than 2 hours per week, 2) low PA; 
moderate PA, mostly without sweating for 2 or more hours 
per week, 3) moderate PA; PA that makes you sweat 1 or 
2 times per week, each time for 30 minutes or more, and 
4) high PA; PA that makes you sweat 3 or more times per 
week, each time for 30 minutes or more. Answers to this 
question have been shown to correlate with accelerometer 
data recorded during a 7-day period (r = 0.37; P < .001) 
and to work well in correctly discriminating between 
activity groups (P for trend < .001) (30). The questions 
on PA in the HUNT study were more detailed and had 
to be harmonized to fit with the 4 response alternatives 
in the ESTRID questionnaire. In HUNT1 leisure time 
PA was measured by the question “How often do you 
exercise?” with 5 response options ranging from never 
to nearly every day (31). To fit with the ESTRID data, 
categories 1 to 2 were collapsed and PA was classified as 
1) sedentary; exercise less than 1 time per week; 2) low; 
1 time per week, 3) moderate; 2 or 3 times per week and 
4) high; nearly every day. In HUNT2, there were separate 
questions on average number of hours of weekly light 
and hard activity during the last year with 4 response 
options ranging from 0 to 3 or more hours per week 
(32). The answers to these 2  questions were combined 
to indicate average PA in 4 categories; 1)  sedentary; 2 
hours or less of light activity a week and no hard activity, 
2) low; 3 hours or more of light activity a week and no 
hard activity, 3) moderate; 1 to 2 hours of hard activity 
a week, and 4) high; 3 hours or more of hard activity a 
week. In addition, we used data from HUNT1 to obtain 
a more detailed assessment of PA based on information 
frequency, duration (< 15, 15-30, 31-60, or ≥ 60 minutes) 
and intensity (light, moderate, or high) of the activity. 
This information was combined into a summary score by 
a previously described method (33).
Covariates. ESTRID: Body mass index (BMI) was 
calculated based on self-reported weight and height as 
kilograms divided by meters squared (kg/m2). For the 
patients, this information has been validated against their 
medical records with a high degree of accuracy (r = 0.92, 
P < .0001) (6). There were questions on lifetime tobacco 
use, alcohol consumption, and highest attained education. 
Family history of diabetes (FHD) based on questions on 
diabetes in first-degree relatives was available only in 
the ESTRID study and not for the genetic controls from 
the EIRA study. HUNT: BMI was based on measures of 
height and weight from the baseline investigation. The 
baseline questionnaires provided information on highest 
attained education, FHD, smoking history, and alcohol 
consumption.
Statistical analyses. Descriptive statistics were compared 
with χ 2 (proportions), Kruskal-Wallis (medians) and t (means) 
tests and 2-sided P values were calculated. The association 
between PA or genotype with LADA or type 2 diabetes was 
assessed by odds ratios (ORs) with 95% CI estimated by 
conditional logistic regression for the ESTRID case-control 
data. ESTRID controls were used in the overall analyses of 
PA (to gain power and to be able to adjust for FHD), and the 
“genetic controls” served as reference in all analyses including 
genetic data (because we did not have genetic information for 
the ESTRID controls). Corresponding hazard ratios (HRs) 
with CIs were calculated by proportional Cox regression 
for the HUNT prospective data, modeled with age as the 
underlying time scale. Participants in HUNT were followed 
from age at baseline until age at onset of diabetes, death, or 
age at follow-up (in HUNT2 or HUNT3). For convenience, 
we use the term relative risk (RR) to describe the effect 
estimates. In addition to presenting study-specific RRs, we 
performed a meta-analysis by pooling the risk-estimates in 
ESTRID and HUNT with the inverse variance method (34). 
These pooled RRs will be presented throughout the paper 
unless otherwise stated. In the main analysis, PA was divided 
into 4 categories (sedentary vs low, moderate, or high activity) 
and into 2 groups (sedentary vs active [low, moderate or high 
activity]) when stratified by genotypes of HLA (high vs low/
intermediate risk), TCF7L2-rs7903146 (TT/TC vs CC), and 
FTO-rs9939609 (AA/AT vs TT). Model 1 was adjusted for 
age, sex (the matching variables in the genetic analyses), and 
smoking (never, former, current) and, except in the analyses 
including genetic information, by FHD (yes vs no). Model 
2 was additionally adjusted for BMI, which was considered 
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“Results” unless otherwise specified. Additional adjustment 
for alcohol consumption (abstainers, low, moderate, or high 
consumers) and education (primary school, upper secondary 
school, or university) did not change the effect estimates; 
these variables were therefore not included in the final 
models. We conducted sensitivity analyses in HUNT based on 
a stricter definition of LADA (ie, no insulin treatment during 
the first year of diagnosis) and a PA summary score including 
intensity and duration of the PA, available for a subset of the 
population. In ESTRID we repeated the main analysis of PA 
and LADA/type 2 diabetes using genetic controls to assess 
whether results were comparable to those based on controls 
from ESTRID. Statistical Analysis Software (SAS) 9.4 (SAS 
Institute) was used for all statistical computations.
Results
Characteristics
In ESTRID, individuals with LADA were younger and 
leaner, more likely to be treated with insulin, had lower 
insulin secretion, and were less insulin resistant than those 
with type 2 diabetes. Comparing controls from ESTRID 
to the genetic controls from EIRA showed that the latter 
were more likely to be female (because rheumatoid arth-
ritis is more common among women); this was handled 
by matching to the diabetes cases. In HUNT, LADA pa-
tients were less likely to have first-degree FHD but were 
more often treated with insulin and had lower levels of 
C-peptide than patients with type 2 diabetes (Table 1).
Genotype and risk of latent autoimmune diabetes 
in adults and type 2 diabetes
As previously reported in these populations (16), LADA 
was strongly associated with HLA high-risk genotypes 
RRpooled 2.59 (95% CI, 2.08-3.22) and tended to be asso-
ciated with TCF7L2rs7903146 (RRpooled 1.18, 95% CI, 0.96-
1.43) and FTOrs9939609 (RRpooled 1.24, 95% CI, 1.00-1.54). 
Type 2 diabetes was associated with TCF7L2 (RRpooled 
1.46, 95% CI, 1.35-1.59) and FTO (RRpooled 1.15, 95% CI 
1.06-1.26) but not with HLA (RRpooled 0.94, 95% CI, 0.86-
1.02). Adjusting for the other genotypes did not change 
these estimates (data not shown).
Physical activity, latent autoimmune diabetes in 
adults, and type 2 diabetes
High PA, corresponding to exercising for at least 30 min-
utes on at least 3 occasions per week, was associated 
with reduced incidence of LADA (RRpooled 0.61, 95% CI, 
0.43-0.86), but the association was eliminated after fur-
ther adjustment for BMI (RRpooled 0.90, 95% CI, 0.63-1.29) 
(see Fig. 1, ESM Table 1) (19). Incidence of type 2 diabetes 
was also reduced in individuals with high PA (RRpooled 0.49, 
95% CI, 0.42-0.56), and this association was attenuated 
but remained after adjustment for BMI (RRpooled 0.72, 95% 
CI, 0.62-0.84) (see Fig. 1). No appreciable differences were 
seen in the study-specific analyses even though numbers 
were smaller and CIs wider, that is, the most active indi-
viduals had the lowest incidence of diabetes (ESM Table 
1)  (19). Results were similar when PA was analyzed in 2 
groups (active vs sedentary) (ESM Table 2) (19).
Stratification by genotype
Stratification by genotypes indicated that the reduced inci-
dence of LADA associated with PA (active vs inactive) ap-
plied only to individuals with low-risk genotypes of HLA; 
RRpooled 0.49 (95% CI, 0.33-0.72), FTO; RRpooled 0.51 
(95% CI, 0.32-0.79), and TCF7L2; RRpooled 0.62 (95% CI, 
0.45-0.87), whereas no association was seen in carriers of 
the high-risk variants (see Fig. 2). Furthermore, the reduced 
incidence associated with PA remained even after adjust-
ment for BMI in low-risk carriers of HLA and FTO geno-
types. For type 2 diabetes, the association with PA did not 
appear to be modified by either TCF7L2, FTO, or HLA 
(see Fig.  2). Study-specific estimates were similar, that is, 
high PA was associated with a reduced incidence of LADA 
primarily in individuals without the high-risk genetic vari-
ants both in ESTRID and HUNT (ESM Table 3) (19). The 
results were also comparable when we analyzed the inci-
dence of LADA/type 2 diabetes in relation to PA in four 
categories, stratified by genotype (ESM Table 4) (19).
Clinical characteristics of latent autoimmune 
diabetes in adults and type 2 diabetes by level of 
physical activity
In ESTRID, sedentary compared to active LADA patients 
had a more type-2 like phenotype with higher mean BMI, 
median HOMA-IR, and HOMA-β (see Table 2). In HUNT, 
numbers were small, and no clear differences were seen 
between sedentary and active LADA patients (data not 
shown). For type 2 diabetes patients in ESTRID, sedentary 
vs active individuals had higher levels of BMI, C-peptide, 
and HOMA-IR.
Sensitivity analyses
Separate analyses of the overall association between 
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reference (ESM Table 5)  (19) indicated similar results as 
those based on controls sampled within the ESTRID study 
(ESM Table 1) (19). When we used a more detailed assess-
ment of PA, including duration and intensity of the activity, 
that was available for a subset of the HUNT population, 
the association between PA and LADA/type 2 diabetes 
was similar to that seen in the overall analyses (ESM Table 
6) (19). Separate analysis of the HUNT data with a stricter 
LADA definition, that is, no insulin treatment, also indi-
cated similar results regarding the association with PA as 
the main analyses (ESM Table 7) (19).
Discussion
High PA corresponding to at least 30 minutes of moderate 
activity, 3 times per week, was associated with a 40% 
lower incidence of LADA. The lower incidence was elim-
inated after adjustment for BMI, suggesting that a poten-
tial effect is mediated by reduced adiposity, alternatively 
that BMI is confounding the association between LADA 
and PA. Separate analyses in individuals with genetic sus-
ceptibility to HLA, TCF7L2, and FTO genotypes reveal 
that high PA is associated with lower incidence of LADA 
only in individuals who do not carry high-risk variants, 
and this association was seen even after adjustment for 
BMI. The association between PA and type 2 diabetes was 
stronger than between PA and LADA, and incidence was 
lower in those with high PA irrespective of the genetic risk 
variants.
Our findings indicate that PA may reduce the incidence 
of LADA through the same mechanism linking PA to type 
2 diabetes, namely through beneficial effects on body 
weight and improved insulin sensitivity (1, 3). In contrast, 
our data did not support that PA inhibits autoimmunity 
because active individuals had higher GADA levels, worse 
β-cell function, and lower levels of C-peptide than those 
who were sedentary. We can only speculate on why PA is 
associated with a lower incidence of LADA only in individ-
uals without genetic susceptibility to diabetes; the HLA-
DRB1 and HLA-DQB1 genotypes are the main risk factors 
for β-cell autoimmunity and loss of β-cell function leading 
to type 1 diabetes (35). Risk variants of TCF7L2 have also 
been linked to reduced insulin secretion (36). One inter-
pretation of our findings is therefore that any beneficial 
effects on body weight and insulin sensitivity conferred by 
PA will have minor influence on the risk of developing dia-
betes in individuals carrying these risk variants, because 
lack of insulin may be the main driver in disease develop-
ment. Why the same results apply to carriers of the FTO 
risk variant is not clear. Importantly, these results should be 
interpreted with caution; this is the first study to address 
the association between PA and LADA in relation to gen-
etic susceptibility, and extensions and replications are 
clearly warranted. It should also be noted that the ana-
lyses of PA by genotype were hampered by relatively low 
numbers and overlapping CIs. Still, these findings fit with 
previous observations that high consumption of sweetened 
beverages only increases the risk of LADA in individuals 
Figure 1. Pooled relative risks (RRs) and 95% CI of latent autoimmune diabetes in adults (LADA) and type 2 diabetes in relation to physical activity 
(PA) in 4 groups (sedentary vs low, moderate, or high activity). Model 1 is adjusted for age, sex, smoking, and family history of diabetes. Model 2 is 
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without HLA risk genotypes (37). This would suggest that 
the influence of environmental factors in the etiology of 
LADA, and thus opportunities for lifestyle interventions, 
are larger in individuals without genetic susceptibility to 
diabetes. We have recently observed that the combination 
of HLA risk genotypes and overweight confers an 8-fold 
increased risk of LADA (16). It seems reasonable that a 
positive effect of PA on body weight and insulin sensitivity 
Figure 2. Pooled relative risks (RRs) and 95% CI of latent autoimmune diabetes in adults (LADA) and type 2 diabetes in relation to physical activity 
(PA) in 2 groups (active vs sedentary) stratified by high and low/intermediate risk genotypes of human leukocyte antigen (HLA), transcription factor 
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may not be enough to counteract the influence of such 
strong risk factors.
Consistent with previous studies (1), we find a 50% 
lower incidence of type 2 diabetes in individuals engaging 
in high PA vs those who are sedentary, and the risk reduc-
tion seemed equally strong in carriers and noncarriers of 
the TCF7L2 and FTO risk variants. Previous data on the 
topic are limited but this observation fits with results from 
the EPIC InterAct study; no synergistic effect was found be-
tween PA and a genetic risk score including both TCF7L2 
and FTO (38). Previous studies also show that PA attenu-
ates the excess risk of obesity conferred by risk variants 
of FTO (17). These findings indicate that lifestyle interven-
tions can reduce the incidence of type 2 diabetes in genetic-
ally predisposed individuals, which is in line with previous 
findings from the Diabetes Prevention Program (39). The 
different results seen for LADA and type 2 diabetes in terms 
of effect modification by genetic susceptibility may be at-
tributed to the fact that insulin resistance plays a relatively 
smaller role in the pathogenesis of LADA.
This study has several strengths, including the large 
number of LADA patients (> 600), the detailed information 
on lifestyle, clinical, and genetic factors, validated questions 
on PA (30-32), and we also had the opportunity to replicate 
the analyses in 2 populations: the Norwegian prospective 
HUNT study and ESTRID, which is a Swedish case-control 
study that recruits incident cases through from the ANDIS 
biobank. A  limitation was that the PA questions differed 
in their phrasing and number of response options across 
studies, which hampers comparability. A further limitation 
is that the PA questions in ESTRID could not distinguish 
between PA of different intensity; still, sensitivity analyses 
in HUNT, including intensity and duration of the activity, 
showed similar results. In the ESTRID study, the PA in-
formation was reported retrospectively and may therefore 
be afflicted with recall bias if cases report differently from 
controls. If individuals with diabetes tend to underestimate 
their previous PA, this will lead to an overestimation of 
an inverse association between PA and LADA/type 2 dia-
betes. In this context it is important to note that results 
based on ESTRID were similar to those based on data from 
the prospective HUNT study, in which information on PA 
was obtained several years prior to diagnosis. With pro-
spective data any misclassification of PA can be expected 
to be independent of future disease status and therefore 
lead to diluted rather than overestimated associations. 
A long time between the PA assessment and diabetes onset 
will also lead to misclassification of PA and diluted associ-
ations. Importantly, our findings regarding PA and type 2 
diabetes based on ESTRID as well as HUNT were in line 
with a large number of previous prospective studies (1, 2) 
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to adjust for a range of potential confounders, but unmeas-
ured confounding or crude assessment of confounders, 
including self-reported information on BMI in ESTRID, 
could still have influenced the results.
The definition of LADA is in line with commonly used 
criteria (5) but the criterion for distinguishing LADA from 
type 1 diabetes patients differed across studies; in ESTRID 
we used C-peptide levels as an indicator of remaining in-
sulin production, whereas we used lack of insulin treatment 
within the first year after diagnosis in HUNT (sensitivity 
analysis). The specificity of the GADA assay was high but 
some type 2 diabetes patients may have been misclassified 
as having LADA, and this could contribute to an associ-
ation with PA. In HUNT, GADA was measured on partici-
pation in the survey rather than at time of diagnosis, which 
could have been several years earlier. Because GADA can 
fade over time (40), some false-negative LADA patients may 
have been included in the type 2 diabetes group. However, 
GADA has proved to be more stable in LADA than in type 
1 diabetes patients (5). Moreover, none of those who de-
veloped type  2 diabetes between HUNT2 and HUNT3 
were GADA positive at HUNT2 (41). Notably, there was 
a strong association between the HLA high-risk genotypes 
and LADA, but not with type 2 diabetes, indicating that the 
rate of misclassified patients is low. GADA was the only 
available autoantibody, but it has been shown to be by far 
the most prevalent autoantibody in LADA (40, 42). Using 
controls borrowed from another study is an additional 
drawback. The validity of this approach is supported by 
the finding of similar associations between PA and LADA/
type 2 diabetes irrespective of whether the original controls 
or the genetic controls served as reference. Finally, it is 
known from previous studies (43) that LADA populations 
are heterogeneous in terms of clinical characteristics, ethni-
city, and genetic makeup, and it remains to be seen whether 
these findings can be generalized to populations outside 
Scandinavia.
In conclusion, this study indicates that PA may prevent 
or postpone LADA through similar mechanistic pathways 
linking PA to type 2 diabetes but only in individuals with 
low genetic risk. The risk reduction does not seem to apply 
to individuals with genetic susceptibility in whom a poten-
tial beneficial effect of PA may not be enough to prevent 
LADA from developing.
Acknowledgments
We wish to thank all administrative and laboratory personnel, 
nurses and research team members and all study participants for 
their generous contributions to the study. Some of the data were 
presented as an abstract at the 54th EASD (European Association 
for the Study of Diabetes) annual meeting in 2018.
Financial Support: ESTRID received funding from the Swedish 
Research Council (GA 2018–03035), the Swedish Research Council 
for Health, Working life and Welfare (GA 2018-00337), the Swed-
ish Diabetes Foundation, and the Novo Nordisk Foundation. Fund-
ing for EIRA was provided by the Swedish Research Council, the 
Swedish Research Council for Health, Working Life and Welfare, the 
Swedish Rheumatic Foundation, the AFA Insurance Company, and 
Stockholm County Council. Financial support for ANDIS came from 
the Swedish Research Council and the European Research Council 
Advanced Researcher grant (GA 269045 to L.G.  and A.L.F.—the 
Swedish Research Council funding for clinical research). The HUNT 
Study is a collaboration between the HUNT Research Centre (Fac-
ulty of Medicine and Health Sciences, NTNU, Norwegian University 
of Science and Technology), Nord-Trøndelag County Council, Cen-
tral Norway Regional Health Authority, and the Norwegian Institute 
of Public Health. GlaxoSmithKline Norway financially supported 
the diabetes study at HUNT2 and HUNT3 through NTNU. The 
genotyping in the HUNT Study was financed by the National Insti-
tutes of Health (NIH), University of Michigan, The Research Council 
of Norway, and Central Norway Regional Health Authority and the 
Faculty of Medicine and Health Sciences, NTNU. The genotype qual-
ity control and imputation have been conducted by the K.G. Jebsen 
Center for Genetic Epidemiology, Department of Public Health and 
Nursing, Faculty of Medicine and Health Sciences, NTNU.
Author Contributions: All authors contributed to the interpret-
ation of the results and critically revised and approved the final 
version of the manuscript. Contributions to the data collection was 
made by S.C., R.H., and T.A. (ESTRID), L.G., E.A., T.T. (ANDIS), 
M.M., P.-O.C. (ANDiU), L.A. (EIRA), E.P.S., V.G., and B.O.Å. 
(HUNT). T.A. contributed statistical expertise. S.C. was responsible 
for conceptualizing the research objectives and designed the study 
and thoroughly revised the manuscript. R.H. developed the object-
ives of the study and was responsible for drafting of the manuscript 
and analyzing the data and responsible for the integrity of the work 
as a whole.
Additional Information
Correspondence and Reprint Requests: Rebecka Hjort, PhD, In-
stitute of Environmental Medicine, Karolinska Institutet, Nobels 
väg 13, SE-17177 Stockholm, Sweden. E-mail: rebecka.hjort@
ki.se.
Disclosure Summary: The authors have nothing to disclose.
Data Availability: Restrictions apply to the availability of data 
generated or analyzed during this study to preserve patient confi-
dentiality or because they were used under license. The correspond-
ing author will on request detail the restrictions and any conditions 
under which access to some data may be provided.
References
 1. Aune  D, Norat  T, Leitzmann  M, Tonstad  S, Vatten  LJ. 
Physical activity and the risk of type 2 diabetes: a systematic 
review and dose-response meta-analysis. Eur J Epidemiol. 
2015;30(7):529-542.
 2. Tuomilehto J, Lindström J, Eriksson JG, et al; Finnish Diabetes 
Prevention Study Group. Prevention of type 2 diabetes mellitus 
by changes in lifestyle among subjects with impaired glucose 







/article/105/11/e4112/5896587 by guest on 05 January 2021
The Journal of Clinical Endocrinology & Metabolism, 2020, Vol. 105, No. 11 e4122
 3. Bird SR, Hawley JA. Update on the effects of physical activity 
on insulin sensitivity in humans. BMJ Open Sport Exerc Med. 
2016;2(1):e000143.
 4. Heiskanen MA, Motiani KK, Mari A, et  al. Exercise training 
decreases pancreatic fat content and improves beta cell func-
tion regardless of baseline glucose tolerance: a randomised con-
trolled trial. Diabetologia. 2018;61(8):1817-1828.
 5. Tuomi T, Santoro N, Caprio S, Cai M, Weng J, Groop L. The 
many faces of diabetes: a disease with increasing heterogeneity. 
Lancet. 2014;383(9922):1084-1094.
 6. Hjort  R, Ahlqvist  E, Carlsson  PO, et  al. Overweight, obesity 
and the risk of LADA: results from a Swedish case-control 
study and the Norwegian HUNT Study. Diabetologia. 
2018;61(6):1333-1343.
 7. Carlsson  E, Ludvigsson  J, Huus  K, Faresjö  M. High physical 
activity in young children suggests positive effects by altering 
autoantigen-induced immune activity. Scand J Med Sci Sports. 
2016;26(4):441-450.
 8. Carlsson  S, Midthjell  K, Tesfamarian  MY, Grill  V. Age, over-
weight and physical inactivity increase the risk of latent auto-
immune diabetes in adults: results from the Nord-Trøndelag 
Health Study. Diabetologia. 2007;50(1):55-58.
 9. Tuomi T, Carlsson A, Li H, et al. Clinical and genetic charac-
teristics of type 2 diabetes with and without GAD antibodies. 
Diabetes. 1999;48(1):150-157.
 10. Cousminer  DL, Ahlqvist  E, Mishra  R, et  al; Bone Mineral 
Density in Childhood Study. First genome-wide association 
study of latent autoimmune diabetes in adults reveals novel in-
sights linking immune and metabolic diabetes. Diabetes Care. 
2018;41(11):2396-2403.
 11. Horton V, Stratton I, Bottazzo GF, et al. Genetic heterogeneity 
of autoimmune diabetes: age of presentation in adults is in-
fluenced by HLA DRB1 and DQB1 genotypes (UKPDS 43). 
UK Prospective Diabetes Study (UKPDS) group. Diabetologia. 
1999;42(5):608-616.
 12. Cervin C, Lyssenko V, Bakhtadze E, et al. Genetic similarities 
between latent autoimmune diabetes in adults, type 1 diabetes, 
and type 2 diabetes. Diabetes. 2008;57(5):1433-1437.
 13. Lukacs  K, Hosszufalusi  N, Dinya  E, Bakacs  M, Madacsy  L, 
Panczel P. The type 2 diabetes-associated variant in TCF7L2 is 
associated with latent autoimmune diabetes in adult Europeans 
and the gene effect is modified by obesity: a meta-analysis and 
an individual study. Diabetologia. 2012;55(3):689-693.
 14. Andersen MK, Sterner M, Forsén T, et al. Type 2 diabetes sus-
ceptibility gene variants predispose to adult-onset autoimmune 
diabetes. Diabetologia. 2014;57(9):1859-1868.
 15. Pettersen E, Skorpen F, Kvaløy K, Midthjell K, Grill V. Genetic 
heterogeneity in latent autoimmune diabetes is linked to 
various degrees of autoimmune activity: results from the Nord-
Trøndelag Health Study. Diabetes. 2010;59(1):302-310.
 16. Hjort R, Löfvenborg JE, Ahlqvist E, et al. Interaction between 
overweight and genotypes of HLA, TCF7L2, and FTO in rela-
tion to the risk of latent autoimmune diabetes in adults and type 
2 diabetes. J Clin Endocrinol Metab. 2019;104(10):4815-4826.
 17. Kilpeläinen TO, Qi L, Brage S, et  al. Physical activity attenu-
ates the influence of FTO variants on obesity risk: a meta-
analysis of 218,166 adults and 19,268  children. PloS Med. 
2011;8(11):e1001116.
 18. Rasouli B, Andersson T, Carlsson PO, et al. Smoking and the 
risk of LADA: results from a Swedish population-based case-
control study. Diabetes Care. 2016;39(5):794-800.
 19. Hjort  R, Ahlqvist  E, Alfredsson  L, et  al. Data from: Physical 
activity, genetic susceptibility and the risk of latent auto-
immune diabetes in adults and type 2 diabetes. figshare. 
2020. Deposited September 5, 2020. https://doi.org/10.6084/
m9.figshare.12921719.
 20. Ahlqvist E, Storm P, Käräjämäki A, et al. Novel subgroups of 
adult-onset diabetes and their association with outcomes: a 
data-driven cluster analysis of six variables. Lancet Diabetes 
Endocrinol. 2018;6(5):361-369.
 21. Vandenbroucke  JP, Pearce N. Case-control studies: basic con-
cepts. Int J Epidemiol. 2012;41(5):1480-1489.
 22. Källberg  H, Ding  B, Padyukov  L, et  al; EIRA Study Group. 
Smoking is a major preventable risk factor for rheumatoid arth-
ritis: estimations of risks after various exposures to cigarette 
smoke. Ann Rheum Dis. 2011;70(3):508-511.
 23. Rahmati K, Lernmark A, Becker C, et al. A comparison of serum and 
EDTA plasma in the measurement of glutamic acid decarboxylase 
autoantibodies (GADA) and autoantibodies to islet antigen-2 (IA-
2A) using the RSR radioimmunoassay (RIA) and enzyme linked im-
munosorbent assay (ELISA) kits. Clin Lab. 2008;54(7-8):227-235.
 24. Oxford Centre for Diabetes, Endocrinology & Metabolism. 
Diabetes Trial Unit. HOMA Calculator. http://www.dtu.ox.ac.
uk/homacalculator. Accessed June 2, 2013.
 25. Nguyen  C, Varney  MD, Harrison  LC, Morahan  G. Definition of 
high-risk type 1 diabetes HLA-DR and HLA-DQ types using only three 
single nucleotide polymorphisms. Diabetes. 2013;62(6):2135-2140.
 26. Krokstad  S, Langhammer  A, Hveem  K, et  al. Cohort 
profile: the HUNT Study, Norway. Int J Epidemiol. 
2013;42(4):968-977.
 27. Midthjell K, Holmen J, Bjørndal A, Lund-Larsen G. Is question-
naire information valid in the study of a chronic disease such 
as diabetes? The Nord-Trøndelag diabetes study. J Epidemiol 
Community Health. 1992;46(5):537-542.
 28. Mishra R, Chesi A, Cousminer DL, et al; Bone Mineral Density 
in Childhood Study. Relative contribution of type 1 and type 2 
diabetes loci to the genetic etiology of adult-onset, non-insulin-
requiring autoimmune diabetes. BMC Med. 2017;15(1):88.
 29. Wellcome Trust Case Control Consortium. Genome-wide asso-
ciation study of 14,000 cases of seven common diseases and 
3,000 shared controls. Nature. 2007;447(7145):661-678.
 30. Sepp H, Ekelund U, Becker W. Enkätfrågor om kost och fysisk 
aktivitet bland vuxna. Livsmedelverket, rapport 21 [article in 
Swedish]; 2004. https://www.livsmedelsverket.se/globalassets/
publikationsdatabas/rapporter/2004/rapp-21-hela.pdf. 
Accessed January 5, 2014.
 31. Kurtze N, Rangul V, Hustvedt BE, Flanders WD. Reliability and 
validity of self-reported physical activity in the Nord-Trøndelag 
Health Study: HUNT 1. Scand J Public Health. 2008;36(1):52-61.
 32. Kurtze N, Rangul V, Hustvedt BE, Flanders WD. Reliability and 
validity of self-reported physical activity in the Nord-Trøndelag 
Health Study (HUNT 2). Eur J Epidemiol. 2007;22(6):379-387.
 33. Hjerkind KV, Stenehjem JS, Nilsen TI. Adiposity, physical ac-
tivity and risk of diabetes mellitus: prospective data from 








/article/105/11/e4112/5896587 by guest on 05 January 2021
e4123  The Journal of Clinical Endocrinology & Metabolism, 2020, Vol. 105, No. 11
 34. Hartung  J, Knapp  G, Sinha  BK. Statistical Meta-Analysis With 
Applications. Hoboken, NJ: John Wiley & Sons; 2008. ISBN 
978-0-470-29089-7.
 35. Pociot F, Lernmark Å. Genetic risk factors for type 1 diabetes. 
Lancet. 2016;387(10035):2331-2339.
 36. Lyssenko V, Lupi R, Marchetti P, et al. Mechanisms by which 
common variants in the TCF7L2 gene increase risk of type 2 
diabetes. J Clin Invest. 2007;117(8):2155-2163.
 37. Löfvenborg  JE, Ahlqvist  E, Alfredsson  L, et  al. Genotypes of 
HLA, TCF7L2, and FTO as potential modifiers of the associ-
ation between sweetened beverage consumption and risk of 
LADA and type 2 diabetes. Eur J Nutr. 2020;59(1):127-135.
 38. Langenberg C, Sharp SJ, Franks PW, et al. Gene-lifestyle inter-
action and type 2 diabetes: the EPIC interact case-cohort study. 
PloS Med. 2014;11(5):e1001647.
 39. Florez JC, Jablonski KA, Bayley N, et al; Diabetes Prevention 
Program Research Group. TCF7L2 polymorphisms and 
progression to diabetes in the Diabetes Prevention Program. N 
Engl J Med. 2006;355(3):241-250.
 40. Sørgjerd EP, Skorpen F, Kvaløy K, Midthjell K, Grill V. Time dy-
namics of autoantibodies are coupled to phenotypes and add to 
the heterogeneity of autoimmune diabetes in adults: the HUNT 
study, Norway. Diabetologia. 2012;55(5):1310-1318.
 41. Sørgjerd  EP, Thorsby  PM, Torjesen  PA, Skorpen  F, Kvaløy  K, 
Grill  V. Presence of anti-GAD in a non-diabetic population of 
adults; time dynamics and clinical influence: results from the 
HUNT Study. BMJ Open Diabetes Res Care. 2015;3(1):e000076.
 42. Hawa MI, Kolb H, Schloot N, et al; Action LADA Consortium. 
Adult-onset autoimmune diabetes in Europe is prevalent with 
a broad clinical phenotype: Action LADA 7. Diabetes Care. 
2013;36(4):908-913.
 43. Buzzetti R, Zampetti S, Maddaloni E. Adult-onset autoimmune 
diabetes: current knowledge and implications for management. 







/article/105/11/e4112/5896587 by guest on 05 January 2021
